Insamo launches with $12m funding to develop best-in-class membrane-permeable macrocyclic peptides
"Turn-key" solution from Insamo to revolutionise drug discovery
26-Feb-2024 -
Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in ...
artificial intelligence
drug discovery
investments
+5